Skip to main content
SpringerLink
Log in

An update on bisphosphonates

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Over the past 15 years, bisphosphonates have been demonstrated as effective therapy for the treatment of osteoporosis based on their ability to suppress bone turnover resulting in increased bone mineral content and increased bone strength. The mechanism of action at the cellular level has been identified, and the more potent nitrogen-containing bisphosphonates clearly have reduced the risk of vertebral and nonvertebral fractures in patients with osteoporosis. Future use of these therapies is evolving to less frequent administration, and the interaction with anabolic therapies is presently being defined. Data to date support long-term safety with bisphosphonates in small numbers of patients treated for 5 to 10 years, and continued vigilant follow-up of the post-marketing experience will be necessary to determine if sustained bone turnover suppression is associated with rare musculoskeletal adverse events. Further development of bisphosphonates as adjunctive therapy to reduce bone metastases is in progress, and trials evaluating bisphosphonates as a structure modifying agent in osteoarthritis are nearing completion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Russell RGG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporosis Int 1999, S66-S80. This article is an excellent review of mechanism of action of BPs at a cellular level that differentiates the BPs.

  2. Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281–289.

    Article  PubMed  CAS  Google Scholar 

  3. Mashiba T, Turner CH, Hirano et al.: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524–531.

    Article  PubMed  CAS  Google Scholar 

  4. Odvina CV, Rao DS, Pak CYC, et al.: Adynamic bone disease during bisphosphonate therapy. J Bone Miner Res 2003, 18(suppl):344–346.

    Google Scholar 

  5. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 1998, 280:2077–2082.

    Article  PubMed  CAS  Google Scholar 

  6. Black DM, Thompson DE, Bauer DC, et al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrin Metab 2000, 85:4118–4124.

    Article  CAS  Google Scholar 

  7. Liberman UA, Weiss SR, Broli J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437–1443.

    Article  PubMed  CAS  Google Scholar 

  8. Hosking D, Clair D, Christiansen C, et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998, 338:485–492.

    Article  PubMed  CAS  Google Scholar 

  9. Cummings SR, Black DM, Thompson D, et al.: Effect of alendronate on the risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 277:1159–1164.

    Google Scholar 

  10. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.

    Article  PubMed  CAS  Google Scholar 

  11. Saag K, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292–299.

    Article  PubMed  CAS  Google Scholar 

  12. Schnitzer T, Bone HG, Crepaldi G, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000, 12:1–12.

    CAS  Google Scholar 

  13. Taggart H, Bolognese MA, Lindsay R, et al.: Upper gastrointestinal safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262–270.

    Article  PubMed  CAS  Google Scholar 

  14. Emkey R, Reid I, Mulloy A, et al.: Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 2002, 17(suppl):S139.

    Google Scholar 

  15. Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrin Metab 2000, 85:3109–3115.

    Article  CAS  Google Scholar 

  16. Ensrud K, Santora A, Schwartz A, et al.: The Fracture Intervention Trial Long-Term Extension (FLEX): 3 year interim results. J Bone Miner Res 2003, 18:F348.

    Google Scholar 

  17. Khan AA, Bilzekian JP, Kung AWC, et al.: A double blind randomized placebo-controlled trial of alendronate in primary hyperparathyroidism. J Bone Miner Res 2003, 18:SA421.

    Google Scholar 

  18. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in postmenopausal osteoporosis. JAMA 1999, 282:1344–1352.

    Article  PubMed  CAS  Google Scholar 

  19. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established osteoporosis. Osteoporos Int 2000, 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  20. Goemaere S, Sorensen OH, Johnson TD: Sustained antifracture efficacy of risedronate treatment over 7 years in postmenopausal women. J Bone Miner Res 2003, 18:F346.

    Google Scholar 

  21. McClung MR, Geusens P, Miller PD, et al.: Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001, 344:333–340. This study is the largest randomized clinical trial of a therapy for osteoporosis. Extensive data on the incidence of hip fracture in osteoporotic patients are reported, and this study raises issues of proper study design for evaluating hip fracture risk reduction.

    Article  PubMed  CAS  Google Scholar 

  22. Ringe JD, Dorst A, Faber H: Risedronate reduces vertebral fractures in men with osteoporosis. J Bone Miner Res 2003, in press.

  23. Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fractures in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277–285.

    Article  PubMed  CAS  Google Scholar 

  24. Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103–111.

    Article  PubMed  CAS  Google Scholar 

  25. Graham DY: What the gastroenterologist should know about the gastrintestinal safety of bisphosphonates. Dig Dis Sci 2002, 47:1665–1678.

    Article  PubMed  CAS  Google Scholar 

  26. Borisov NN, Doyle J, Brezovic CP, et al.: Economic evaluation of gastrointestinal events in osteoporotic patients receiving bisphosphonate therapy in a managed care setting. J Bone Miner Res 2003, 18(suppl):336.

    Google Scholar 

  27. Storm T, Thamsborg G, Steiniche T, et al.: Effect of intermittent cuclic etidronate of postmenopausal osteoporosis. N Engl J Med 1990, 322:1265–1271.

    Article  PubMed  CAS  Google Scholar 

  28. Watts NB, Harris ST, Genant HK, et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73–79.

    Article  PubMed  CAS  Google Scholar 

  29. Adachi KD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382–387.

    Article  PubMed  CAS  Google Scholar 

  30. Reginster JY, Christiansen C, Roux C, et al.: Intermittent cyclic tiludronate in the treatment of postmenopausal osteoporosis. Osteoporos Int 2001, 12:169–177.

    Article  PubMed  CAS  Google Scholar 

  31. Peretz A, Body JJ, Dumon JC, et al.: Cyclic pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996, 25:69–75.

    Article  PubMed  CAS  Google Scholar 

  32. Maksymowych WP, Jhangri GS, Fitzgerald AA,et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002,46:766–773.

    Article  PubMed  CAS  Google Scholar 

  33. Kanis JA, McCloskey EV, Beneton MN: Clodronate and osteoporosis. Maturitas 1996, 23:S81-S86.

    Article  PubMed  CAS  Google Scholar 

  34. Diel IJ, Solomayer EF, Costa SD, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357–363.

    Article  PubMed  CAS  Google Scholar 

  35. Wasnich R, Felsenberg D, Lorenc R, et al.: A multinational study demonstrating significant reduction in the incidence of new vertebral fractures with oral and daily and intermittent ibandronate. J Bone Miner Res 2003, 18:F354.

    Google Scholar 

  36. Recker RR, Stakkestad JA, Felsenberg D, et al.: A new treatment paradigm: quarterly injections reduce the risk of fracture in women with postmenopausal osteoporosis. Osteoporos Int 2000, 11:S209.

    Google Scholar 

  37. Adami S, Delmas PD, Christiansen C, et al.: Intravenous ibandronate injections given once every 3 months are effective and well tolerated in the treatment of postmenopausal women. Ann Rheum Dis 2003, in press.

  38. Tanko LB, Riis BJ, Felsenberg D, et al.: Once-weekly ibandronate prevents bone loss in postmenopausal women. J Bone Miner Res 2003, 18:F342.

    Google Scholar 

  39. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661. This study evaluates a new potent investigational BP that potentially could be administered on a yearly basis if fracture risk reduction is demonstrated.

    Article  PubMed  CAS  Google Scholar 

  40. Bhatia A, Chang G, Allsworth A: Zoledronate in the treatment of Paget’s disease. J Bone Miner Res 2003, 18M:394.

    Google Scholar 

  41. Lindsay R, Cosman F, Lobo RA, et al.: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized controlled clinical trial. J Clin Endocrin Metab 1999, 84:3076–3081.

    Article  CAS  Google Scholar 

  42. Harris ST, Eriksen EF, Davidson M, et al.: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrin Metab 2001, 86:1890–1897.

    Article  CAS  Google Scholar 

  43. Greenspan SL, Resnick NM, Parker RA: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. JAMA 2003, 289:2525–2533.

    Article  PubMed  CAS  Google Scholar 

  44. Johnell O, Scheele WH, Lu Y: Additive effects of raloxifene and alendronate on bone mineral density and bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrin Metab 2002, 87:985–992.

    Article  CAS  Google Scholar 

  45. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215. This study, along with Finkelstein et al. [46], is the first to examine this combination therapy and has begun to define the role of antiresorptive and anabolic therapy.

    Article  PubMed  CAS  Google Scholar 

  46. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226.

    Article  PubMed  CAS  Google Scholar 

  47. Ettinger B, San Martin JS, Crans GG, et al.: Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously with an antiresorptive drug. J Bone Miner Res 2003, 18:1055.

    Google Scholar 

  48. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporosis women with parathyroid hormone followed by alendronate. J Clin Endocrin Metab 2000, 85:2129–2134.

    Article  CAS  Google Scholar 

  49. Beary JF: Joint structure modification in osteoarthritis: development of SMOAD drugs. Curr Rheum Reports 2001, 3:506–512.

    Article  Google Scholar 

  50. Spector TD, Conaghan P, Buckland-Wright TC, et al.: Risedronate produces disease modification and symptomatic benefit in the treatment of osteoarthritis. Arthritis Rheum 2003, 48:20.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiant Research, 5939 Harry Hines Boulevard, Suite 400, 75235, Dallas, TX, USA

    Stanley B. Cohen MD

Authors
  1. Stanley B. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, S.B. An update on bisphosphonates. Curr Rheumatol Rep 6, 59–65 (2004). https://doi.org/10.1007/s11926-004-0084-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0084-2

Keywords

Search

Navigation